A retrospective study presented at the San Antonio Breast Cancer Symposium examined whether routine immune markers in the blood can predict response to neoadjuvant (preoperative) chemoimmunotherapy in patients with triple-negative breast cancer (TNBC). The study analyzed commonly available blood markers of patients' immune status before treatment and compared them with pathological complete response after neoadjuvant treatment. The authors reported that certain blood immune markers correlated with a higher likelihood of response to preoperative chemoimmunotherapy. The study was retrospective, that is, it was based on an analysis of pre-existing data, and the results are observational in nature. The specific statistics, sample size, and exact values of correlations were not reported in the article's assigned text. The authors emphasized the need for further prospective studies to verify and confirm these findings.